Valeant Pharmaceutical International and Bill Ackerman, the activist investor who runs Pershing Capital Management, are putting additional pressure on Allergan's shareholders and its board of directors to approve their takeover proposals. Valeant has increased its offer to buy Allergan twice. One week ago, it was prepared to pay a total ...

Buying a membership today will give you:
To continue reading this article register now.